Modeling of red blood cell life-spans in hematologically normal populations

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 5, 2012, Pages 453-462

  Lledó García, Rocío ^a,b   Kalicki, Robert M ^a,c   Uehlinger, Dominik E ^c   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biotin labeled; Hba1c; Life span modeling; Mechanism based model; Pharmacometrics; Red blood cells

Indexed keywords

BIOTIN;

ARTICLE; CELL POPULATION; CELL SURVIVAL; COMPARTMENT MODEL; ERYTHROCYTE; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROCESS DEVELOPMENT;

CELL SURVIVAL; ERYTHROCYTE AGING; ERYTHROCYTES; HUMANS; LIFE EXPECTANCY; LONGEVITY; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RANDOM ALLOCATION;

EID: 84870403999     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9261-5     Document Type: Article

References (33)

1. Alfrey CP, Rice L, Udden MM, Driscoll TB (1997) Neocytolysis: physiological down-regulator of red-cell mass. Lancet 349(9062): 1389-1390
2. Testa U (2004) Apoptotic mechanisms in the control of erythropoiesis. Leukemia 18(7):1176-1199
3. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228(1):1-14
4. Franco RS (2009) The measurement and importance of fed cell survival. Am J Hematol 84:109-114
5. Eadie GS, Brown IW Jr (1953) Red blood cell survival studies. Blood 8(12):1110-1136
6. de Lima JJ (1987) Survival equations for red blood cells with statistical distributions in life spans. Eur J Nucl Med 13(2):76-81
7. Kay MM (1984) Localization of senescent cell antigen on band 3. Proc Natl Acad Sci USA 81(18):5753-5757
8. Kay MM (1990) Senescent cell antigen, band 3, and band 3 mutations in cellular aging. Biomed Biochim Acta 49(2-3): S212-S217
9. Rettig MP, Low PS, Gimm JA, Mohandas N, Wang J, Christian JA (1999) Evaluation of biochemical changes during in vivo erythrocyte senescence in the dog. Blood 93(1):376-384
10. Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51(1):76-89
11. Krzyzanski W, Ramakrishnan R, Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27(5):467-489
12. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26(3-4):295-306
13. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44(9):991-1002
14. Perez-Ruixo JJ, KimkoHC,ChowAT, PiotrovskyV,KrzyzanskiW, JuskoWJ (2005) Population cell life spanmodels for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 32(5-6):767-793
15. Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML (1977) Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 86(4):425-429
16. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33(3):313-343
17. Hamren B, Bjork E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84(2):228-235
18. Kalicki R, Lledó-Garciá R, Karlsson M (2009) Modeling of red blood cell (RBC) Lifespan (LS) in a Hematologically normal population, in PAGE 2009. 2009: St Petersburg
19. Mock DM, Lankford GL, Widness JA, Burmeister LF, Kahn D, Strauss RG (1999) Measurement of red cell survival using biotinlabeled red cells: validation against 51Cr-labeled red cells. Transfusion 39(2):156-162
20. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH (2008) Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 112(10):4284-4291
21. Mock DM, Lankford GL, Widness JA, Burmeister LF, Kahn D, Strauss RG (2004) RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume. Transfusion 44(3):431-437
22. Franco RS, Lohmann J, Silberstein EB, Mayfield-Pratt G, Palascak M, Nemeth TA, Joiner CH, Weiner M, Rucknagel DL (1998) Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest 101(12):2730- 2740
23. Franco RS, Yasin Z, Lohmann JM, Palascak MB, Nemeth TA, Weiner M, Joiner CH, Rucknagel DL (2000) The survival characteristics of dense sickle cells. Blood 96(10):3610-3617
24. Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL (2006) The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 108(3):1073-1076
25. Ribbing J, Hamren B, Svensson MK, Karlsson MO (2010) A model for glucose, insulin and beta-cell dynamics in participants with insulin resistance and patients with type 2 diabetes. J Clin Pharmacol 50(8):861-872
26. Purves RD (1994) Numerical estimation of the noncompartmental pharmacokinetic parameters variance and coefficient of variation of residence times. J Pharm Sci 83(2):202-205
27. Karlsson MO, Holford NH (2008) Tutorial on visual predictive checks. http://www.page-meeting.org/?abstract=1434, in PAGE meeting. 2008: Marseille
28. Jonsson EN, Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1): 51-64
29. Giovanetti S, Balestri P, Cioni L (1965) Spontaneous in vitro autohemolysis of blood from chronic uremic patients. Clin Sci 29:407-416
30. Korell J, Coulter CV, Duffull SB (2011) A statistical model for red blood cell survival. J Theor Biol 268(1):39-49
31. Korell J, Vos FE, Coulter CV, Schollum JB, Walker RJ, Duffull SB (2011) Modeling red blood cell survival data. J Pharmacokinet Pharmacodyn 38(6):787-801
32. Krzyzanski W (2011) Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn 38(2):179-204
33. Ladyzynski P, Wojcicki JM, Bak M, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W (2008) Validation of hemoglobin glycation models using glycemia monitoring in vivo and culturing of erythrocytes in vitro. Ann Biomed Eng 36(7): 1188-1202